Keeping pace with ACE: Are ACE inhibitors and angiotensin II type 1 receptor antagonists potential doping agents?

Sports Medicine

Volumn 38, Issue 12, 2008, Pages 1065-1079

  Wang, Pei ^a   Fedoruk, Matthew N ^a   Rupert, Jim L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; TRANDOLAPRIL;

ATHLETE; CONGESTIVE HEART FAILURE; DOPING; DOSE RESPONSE; DRUG DOSE COMPARISON; ENDURANCE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GENE DELETION; GENE INSERTION; GENOTYPE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MOTOR PERFORMANCE; MUSCLE FUNCTION; MUSCLE TRAINING; NONHUMAN; OXYGEN CONSUMPTION; PHARMACOGENOMICS; PHENOTYPE; PHYSICAL PERFORMANCE; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 56749101932     PISSN: 01121642     EISSN: None     Source Type: Journal    
DOI: 10.2165/00007256-200838120-00008     Document Type: Review

References (105)

1. Taylor RR, Mamotte CD, Fallon K, et al. Elite athletes and the gene for angiotensin-converting enzyme. J Appl Physiol 1999; 87 (3): 1035-7
2. Woods D, Hickman M, Jamshidi Y, et al. Elite swimmers and the D allele of the ACE I/D polymorphism. Hum Genet 2001; 108 (3): 230-2
3. Diet F, Graf C, Mahnke N, et al. ACE and angiotensinogen gene genotypes and left ventricular mass in athletes. Eur J Clin Invest 2001; 31 (10): 836-42
4. Scanavini D, Bernardi F, Castoldi E, et al. Increased frequency of the homozygous II ACE genotype in Italian Olympic endurance athletes. Eur J Hum Genet 2002; 10 (10): 576-7
5. Rankinen T, Wolfarth B, Simoneau JA, et al. No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status. J Appl Physiol 2000; 88 (5): 1571-5
6. Lucia A, Gomez-Gallego F, Chicharro JL, et al. Is there an association between ACE and CKMM polymorphisms and cycling performance status during 3-week races? Int J Sports Med 2005; 26 (6): 442-7
7. Woods DR, Brull D, Montgomery HE. Endurance and the ACE I/D polymorphism. Sci Prog 2000; 83: 317-36
8. Jones A, Montgomery HE, Woods DR. Human performance: a role for the ACE genotype? Exerc Sport Sci Rev 2002; 30 (4): 184-90
9. Kurdi M, De Mello WC, Booz GW. Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components. Int J Biochem Cell Biol 2005; 37 (7): 1357-67
10. Danser AH, Batenburg WW, van den Meiracker AH, et al. ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition? Pharmacol Ther 2007; 113 (3): 607-18
11. Cambien F, Alhenc-Gelas F, Herbeth B, et al. Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. Am J Hum Genet 1988; 43 (5): 774-80
12. Reneland R, Lithell H. Angiotensin-converting enzyme in human skeletal muscle: a simple in vitro assay of activity in needle biopsy specimens. Scand J Clin Lab Invest 1994; 54 (2): 105-11
13. Danser AH. Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 2003; 35 (6): 759-68
14. Van Kats JP, Duncker DJ, Haitsma DB, et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 2000; 102 (13): 1556-63
15. Montgomery HE, Marshall R, Hemingway H, et al. Human gene for physical performance. Nature 1998; 393: 221-2
16. Rupert JL, Kidd KK, Norman LE, et al. Genetic polymorphisms in the renin-angiotensin system in high-altitude and low-altitude Native American populations. Ann Hum Genet 2003; 67 (1): 17-25
17. Gesang L, Liu G, Cen W, et al. Angiotensin-converting enzyme gene polymorphism and its association with essential hypertension in a Tibetan population. Hypertens Res 2002; 25 (3): 481-5
18. Cai Q, Liu HJ, Jiang MC, et al. A study of insertion/delation polymorphism of the angiotensin-converting enzyme gene in pilots [in Chinese]. Yi Chuan 2002; 24 (1): 6-8
19. Gayagay G, Yu B, Hambly B, et al. Elite endurance athletes and the ACE I allele: the role of genes in athletic performance. Hum Genet 1998; 103 (1): 48-50
20. Alvarez R, Terrados N, Ortolano R, et al. Genetic variation in the renin-angiotensin system and athletic performance. Eur J Appl Physiol 2000; 82 (1-2): 117-20
21. Collins M, Xenophontos SL, Cariolou MA, et al. The ACE gene and endurance performance during the South African Ironman Triathlons. Med Sci Sports Exerc 2004; 36 (8): 1314-20
22. Nazarov IB, Woods DR, Montgomery HE, et al. The angiotensin converting enzyme I/D polymorphism in Russian athletes. Eur J Hum Genet 2001; 9 (10): 797-801
23. Scott RA, Moran C, Wilson RH, et al. No association between angiotensin converting enzyme (ACE) gene variation and endurance athlete status in Kenyans. Comp Biochem Physiol A Mol Integr Physiol 2005; 141 (2): 169-75
24. Amir O, Amir R, Yamin C, et al. The ACE deletion allele is associated with Israeli elite endurance athletes. Exp Physiol 2007; 92 (5): 881-6
25. Myerson S, Hemingway H, Budget R, et al. Human angiotensin I-converting enzyme gene and endurance performance. J Appl Physiol 1999; 87 (4): 1313-6
26. Forrester T, McFarlane-Anderson N, Bennett FI, et al. The angiotensin converting enzyme and blood pressure in Jamaicans. Am J Hypertens 1997; 10 (5 Pt 1): 519-24
27. Payne JR, Dhamrait SS, Gohlke P, et al. The impact of ACE genotype on serum ACE activity in a black South African male population. Ann Hum Genet 2007; 71 (Pt 1): 1-7
28. Woods DR, Humphries SE, Montgomery HE. The ACE I/D polymorphism and human physical performance. Trends Endocrinol Metab 2000; 11 (10): 416-20
29. Dekany M, Harbula I, Berkes I, et al. The role of insertion allele of angiotensin converting enzyme gene in higher endurance efficiency and some aspects of pathophysiological and drug effects. Curr Med Chem 2006; 13 (18): 2119-26
30. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, et al. ACE polymorphisms. Circ Res 2006; 98 (9): 1123-33
31. Montgomery H, Brull D. Gene-environment interactions and the response to exercise. Int J Exp Pathol 2000; 81 (5): 283-7
32. Williams AG, Rayson MP, Jubb M, et al. The ACE gene and muscle performance. Nature 2000; 403 (6770): 614
33. Woods DR, World M, Rayson MP, et al. Endurance enhancement related to the human angiotensin I-converting enzyme I-D polymorphism is not due to differences in the cardiorespiratory response to training. Eur J Appl Physiol 2002; 86 (3): 240-4
34. Thompson PD, Tsongalis GJ, Ordovas JM, et al. Angiotensin-converting enzyme genotype and adherence to aerobic exercise training. Prev Cardiol 2006; 9 (1): 21-4
35. Folland J, Leach B, Little T, et al. Angiotensin-converting enzyme genotype affects the response of human skeletal muscle to functional overload. Exp Physiol 2000; 85 (5): 575-9
36. Thomis MA, Huygens W, Heuninckx S, et al. Exploration of myostatin polymorphisms and the angiotensin-converting enzyme insertion/deletion genotype in responses of human muscle to strength training. Eur J Appl Physiol 2004; 92 (3): 267-74
37. Pescatello LS, Kostek MA, Gordish-Dressman H, et al. ACE ID genotype and the muscle strength and size response to unilateral resistance training. Med Sci Sports Exerc 2006; 38 (6): 1074-81
38. Sonna LA, Sharp MA, Knapik JJ, et al. Angiotensin-converting enzyme genotype and physical performance during US Army basic training. J Appl Physiol 2001; 91 (3): 1355-63
39. Montgomery HE, Clarkson P, Dollery C, et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation 1997; 96 (3): 741-7
40. Jasinska A, Krzyzosiak WJ. Repetitive sequences that shape the human transcriptome. FEBS Lett 2004; 567 (1): 136-41
41. Rajeevan H, Osier MV, Cheung KH, et al. ALFRED: the ALelle FREquency Database: update. Nucleic Acids Res 2003; 31 (1): 270-1
42. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/ deletion in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6
43. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart: effect of the deletion/ insertion polymorphism. Circulation 1995; 92 (6): 1387-8
44. Bloem LJ, Manatunga AK, Pratt JH. Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Hypertension 1996; 27 (1): 62-6
45. Foy CA, McCormack LJ, Knowler WC, et al. The angiotensin-I converting enzyme (ACE) gene I/D polymorphism and ACE levels in Pima Indians. J Med Genet 1996; 33: 336-7
46. Faure-Delanef L, Baudin B, Beneteau-Burnat B, et al. Plasma concentration, kinetic constants, and gene polymorphism of angiotensin I-converting enzyme in centenarians. Clin Chem 1998; 44 (10): 2083-7
47. Tamura T, Johanning GL, Goldenberg RL, et al. Effect of angiotensin-converting enzyme gene polymorphism on pregnancy outcome, enzyme activity, and zinc concentration. Obstet Gynecol 1996; 88 (4 Pt 1): 497-502
48. Rossi GP, Narkiewicz K, Cesari M, et al. Genetic determinants of plasma ACE and renin activity in young normotensive twins. J Hypertens 1999; 17 (5): 647-55
49. Sayed-Tabatabaei FA, Schut AF, Hofman A, et al. A study of gene: environment interaction on the gene for angiotensin converting enzyme - a combined functional and population based approach. J Med Genet 2004; 41 (2): 99-103
50. Williams AG, Day SH, Folland JP, et al. Circulating angiotensin converting enzyme activity is correlated with muscle strength. Med Sci Sports Exerc 2005; 37 (6): 944-8
51. 2max or mechanical efficiency in women. Eur J Appl Physiol 2007; 99 (1): 11-8
52. Suehiro T, Morita T, Inoue M, et al. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet 2004; 115 (2): 91-6
53. Fedorova L, Fedorov A. Introns in gene evolution. Genetica 2003; 118 (2-3): 123-31
54. Zhu X, Bouzekri N, Southam L, et al. Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet 2001; 68 (5): 1139-48
55. Keavney B, McKenzie CA, Connell JM, et al. Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum Mol Genet 1998; 71 (11): 1745-51
56. Koehle MS, Wang P, Guenette JA, et al. No association between variants in the ACE and angiotensin II receptor 1 genes and acute mountain sickness in Nepalese pilgrims to the Janai Purnima Festival at 4380 metres. High Alt Med Biol 2006; 7 (4): 281-9
57. Cox R, Bouzekri N, Martin S, et al. Angiotensin-1-converting enzyme (ACE) plasma concentration is influenced by multiple ACE-linked quantitative trait nucleotides. Hum Mol Genet 2002; 11 (23): 2969-77
58. Cam FS, Colakoglu M, Sekuri C, et al. Association between the ACE I/D gene polymorphism and physical performance in a homogeneous non-elite cohort. Can J Appl Physiol 2005; 30 (1): 74-86
59. Kanaide H, Ichiki T, Nishimura J, et al. Cellular mechanism of vasoconstriction induced by angiotensin II: it remains to be determined. Circ Res 2003; 93 (11): 1015-7
60. Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens 2005; 18 (9 Pt 2): 134S-41S
61. 2max is associated with ACE genotype in postmenopausal women. J Appl Physiol 1998; 85 (5): 1842-6
62. Roltsch MH, Brown MD, Hand BD, et al. No association between ACE I/D polymorphism and cardiovascular hemodynamics during exercise in young women. Int J Sports Med 2005; 26 (8): 638-44
63. Rankinen T, Pérusse L, Gagnon J, et al. Angiotensin-converting enzyme ID polymorphism and fitness phenotype in the HERITAGE Family Study. J Appl Physiol 2000; 88: 1029-35
64. 2max of Chinese males. Life Sci 2003; 73 (20): 2625-30
65. Zhang B, Tanaka H, Shono N, et al. The I allele of the angiotensin-converting enzyme gene is associated with an increased percentage of slow-twitch type I fibers in human skeletal muscle. Clin Genet 2003; 63 (2): 139-44
66. Williams AG, Dhamrait SS, Wootton PT, et al. Bradykinin receptor gene variant and human physical performance. J Appl Physiol 2004; 96 (3): 938-42
67. ACE Inhibitor Myocardial Infarction Collaborative Group (AIMIC). Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998; 97 (22): 2202-12
68. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003; 91 (12A.): 30H-7H
69. Hebert LA, Falkenhain ME, Nahman Jr NS, et al. ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999; 19 (1): 1-6
70. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002; 113 (5): 409-18
71. Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90 (7): 770-6
72. Louch WE, Ferrier GR, Howlett SE. Losartan improves recovery of contraction and inhibits transient inward current in a cellular model of cardiac ischemia and reperfusion. J Pharmacol Exp Ther 2000; 295 (2): 697-704
73. Opie LH. Angiotensin converting enzyme inhibitors. 3rd ed. Cape Town: University of Cape Town Press, 1999
74. Vescovo G, Dalla Libera L, Serafini F, et al. Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation 1998; 98 (17): 1742-9
75. Corder CN, Rubler S, Deere LF, et al. Effect of cilazapril on exercise tolerance in congestive heart failure. Pharmacology 1993; 46 (3): 148-54
76. Leon AS, McNally C, Casal DC, et al. Enalapril alone and combined with hydrochlorothiazide in the treatment of hypertension: effect on treadmill exercise performance. J Cardiac Rehab 1986; 6: 251-6
77. Gordon NF, Myburgh DP, Neutral JM, et al. Comparison of captopril and conventional step I antihypertensive therapy: effects on exercise performance. J Cardiopulm Rehab 1988; 8: 108-15
78. Vanhees L, Fagard R, Lijnen P, et al. Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen. J Hypertens 1991; 9 (11): 1063-8
79. Guazzi M, Palermo P, Pontone G, et al. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol 1999; 84 (9): 1038-43
80. Pascual Figal DA, de la Morena Valenzuela G, Nicolas Ruiz F, et al. Addition of an angiotensin II receptor blocker to maximal dose of ACE inhibitors in heart failure. Rev Esp Cardiol 2002; 55 (8): 862-6
81. Munzel T, Kurz S, Drexler H. Are alterations of skeletal muscle ultrastructure in patients with heart failure reversible under treatment with ACE-inhibitors [in German]? Herz 1993; 18 Suppl. 1: 400-5
82. Aldigier JC, Huang H, Dalmay F, et al. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993; 21 (2): 289-95
83. Fagard R, Lijnen P, Vanhees L, et al. Hemodynamic response to converting enzyme inhibition at rest and exercise in humans. J Appl Physiol 1982; 53 (3): 576-81
84. Predel HG, Rohden C, Heine O, et al. ACE inhibition and physical exercise: studies on physical work capacity, energy metabolism, and maximum oxygen uptake in well-trained, healthy subjects. J Cardiovasc Pharmacol 1994; 23 Suppl. 1: S25-S8
85. Carre F, Handschuh R, Beillot J, et al. Effects of captopril chronic intake on the aerobic performance and muscle strength of normotensive trained subjects. Int J Sports Med 1992; 13 (4): 308-12
86. Sumukadas D, Witham MD, Struthers AD, et al. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 2007; 177 (8): 867-74
87. Schaufelberger M, Andersson G, Eriksson BO, et al. Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril. Eur Heart J 1996; 17 (11): 1678-85
88. Onder G, Vedova CD, Pahor M. Effects of ACE inhibitors on skeletal muscle. Curr Pharm Des 2006; 12 (16): 2057-64
89. Di Bari M, Van De Poll-Franse LV, Onder G, et al. Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition study. J Am Geriatr Soc 2004; 52 (6): 961-6
90. Minami N, Mori N, Nagasaka M, et al. Effect of high-salt diet or chronic captopril treatment on exercise capacity in normotensive rats. Clin Exp Pharmacol Physiol 2004; 31 (4): 197-201
91. Minami N, Li Y, Guo Q, et al. Effects of angiotensin-converting enzyme inhibitor and exercise training on exercise capacity and skeletal muscle. J Hypertens 2007; 25 (6): 1241-8
92. Bahi L, Koulmann N, Sanchez H, et al. Does ACE inhibition enhance endurance performance and muscle energy metabolism in rats? J Appl Physiol 2004; 96 (1): 59-64
93. Rouyer O, Zoll J, Daussin F, et al. Effect of angiotensin-converting enzyme inhibition on skeletal muscle oxidative function and exercise capacity in streptozotocin-induced diabetic rats. Exp Physiol 2007; 92 (6): 1047-56
94. Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensinconverting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99 (8): 990-2
95. Cooke GA, Williams SG, Marshall P, et al. A mechanistic investigation of ACE inhibitor dose effects on aerobic exercise capacity in heart failure patients. Eur Heart J 2002; 23 (17): 1360-8
96. Williams SG, Cooke GA, Wright DJ, et al. Disparate results of ACE inhibitor dosage on exercise capacity in heart failure: a reappraisal of vasodilator therapy and study design. Int J Cardiol 2001; 77 (2-3): 239-45
97. Ueda S, Meredith PA, Morton JJ, et al. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98 (20): 2148-53
98. Nakano Y, Oshima T, Watanabe M, et al. I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. Am J Hypertens 1997; 10 (9 Pt 1): 1064-8
99. Taylor JS, Ellis GR. Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure. Am J Cardiovasc Drugs 2002; 2 (6): 389-99
100. Benetos A, Cambien F, Gautier S, et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28 (6): 1081-4
101. Hoogeveen AR. The effect of endurance training on the ventilatory response to exercise in elite cyclists. Eur J Appl Physiol 2001; 82 (1-2): 45-51
102. 2max and running performance. Med Sci Sports Exerc 1993; 25 (12): 1393-7
103. Connes P, Perrey S, Varray A, et al. Faster oxygen uptake kinetics at the onset of submaximal cycling exercise following 4 weeks recombinant human erythropoietin (r-HuEPO) treatment. Pflugers Arch 2003; 447 (2): 231-8
104. Thomsen JJ, Rentsch RL, Robach P, et al. Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity. Eur J Appl Physiol 2007; 101 (4): 481-6
105. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354 (23): 2443-51